All In Biotech

Drug Trial Radar · NCT07039578

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis

Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 25, 2025

Primary completion

Jun 30, 2026

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis

Conditions

  • Primary Light-Chain Amyloidosis

Interventions

  • CM336 Injection(Low dose group)Biological

    subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.

  • CM336 Injection(High dose group)Biological

    subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy after CM336 treatmentTime frame: up to 3 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.